Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17565791 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KDM4EMAPK1HPGD | |
| SCHEMBL9429952 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KDM4EMAPK1HPGD | |
| SCHEMBL5503906 | 0.83 | HRH4 (0.51) | SMN1; SMN2HRH4ALDH1A1HSD17B10KMT2A | |
| SCHEMBL2726311 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2HRH4ALDH1A1KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL4020304 | 0.82 | HRH4 (0.50) | SMN1; SMN2HRH4ALDH1A1HSD17B10KMT2A | |
| SCHEMBL4792397 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KDM4EMAPK1ALOX15 | |
| SCHEMBL5503125 | 0.81 | HRH4 (0.52) | SMN1; SMN2HRH4ALDH1A1ALOX15KMT2A | |
| SCHEMBL2726524 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2HRH4ALDH1A1KDM4EMAPK1 | |
| SCHEMBL2726476 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2HRH4ALDH1A1KDM4EMAPK1 | |
| SCHEMBL2420833 | 0.80 | PRKDC (0.73) | SMN1; SMN2ALDH1A1KDM4EMAPK1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010120994-A2 | UREIDOARYL-AND CARBAMOYLARYL-MORPHOLINO- PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | SMN1; SMN2 1256/4885HRH4 1423/4885ALDH1A1 3589/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | SMN1; SMN2 1256/4885HRH4 1423/4885ALDH1A1 3589/4885 |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | SMN1; SMN2 1256/4885HRH4 1423/4885ALDH1A1 3589/4885 |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | SMN1; SMN2 1256/4885HRH4 1423/4885ALDH1A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.